Adaptive Biotechnologies (ADPT) Liabilities and Shareholders Equity (2018 - 2026)

Adaptive Biotechnologies has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $505.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 0.96% year-over-year to $505.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 8.56% YoY) and the FY2025 annual result came in at $512.7 million, down 4.94% from the prior year.
• Liabilities and Shareholders Equity slipped to $505.9 million in Q1 2026 per ADPT's latest filing, from $512.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $884.2 million in Q3 2022 and troughed at $490.6 million in Q3 2025.
• A 5-year average of $656.5 million and a median of $620.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2026: Liabilities and Shareholders Equity fell 23.5% in 2024, then dropped 0.96% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $856.6 million in 2022, then dropped by 22.82% to $661.1 million in 2023, then declined by 18.42% to $539.4 million in 2024, then slipped by 4.94% to $512.7 million in 2025, then slipped by 1.32% to $505.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $505.9 million, $512.7 million, and $490.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.